176 related articles for article (PubMed ID: 6391973)
1. Acarbose treatment of sulfonylurea-treated non-insulin dependent diabetics. A double-blind cross-over comparison of an alpha-glucosidase inhibitor with metformin.
Johansen K
Diabete Metab; 1984 Oct; 10(4):219-23. PubMed ID: 6391973
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.
Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH; Wolever TM
Ann Intern Med; 1994 Dec; 121(12):928-35. PubMed ID: 7734015
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes.
Rosenstock J; Brown A; Fischer J; Jain A; Littlejohn T; Nadeau D; Sussman A; Taylor T; Krol A; Magner J
Diabetes Care; 1998 Dec; 21(12):2050-5. PubMed ID: 9839093
[TBL] [Abstract][Full Text] [Related]
4. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
[TBL] [Abstract][Full Text] [Related]
5. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study.
Lam KS; Tiu SC; Tsang MW; Ip TP; Tam SC
Diabetes Care; 1998 Jul; 21(7):1154-8. PubMed ID: 9653611
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.
Hoffmann J; Spengler M
Am J Med; 1997 Dec; 103(6):483-90. PubMed ID: 9428831
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with acarbose: results of a Canadian multicentre study.
Rodger NW; Chiasson JL; Josse RG; Hunt JA; Palmason C; Ross SA; Ryan EA; Tan MH; Wolever TM
Clin Invest Med; 1995 Aug; 18(4):318-24. PubMed ID: 8549019
[TBL] [Abstract][Full Text] [Related]
8. A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients.
Bayraktar M; Van Thiel DH; Adalar N
Diabetes Care; 1996 Mar; 19(3):252-4. PubMed ID: 8742572
[TBL] [Abstract][Full Text] [Related]
9. Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial.
Josse RG
Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S167-72. PubMed ID: 8529510
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of acarbose, an alpha-glucosidase inhibitor, in uncontrolled non-obese non-insulin dependent diabetes.
Buchanan DR; Collier A; Rodrigues E; Millar AM; Gray RS; Clarke BF
Eur J Clin Pharmacol; 1988; 34(1):51-3. PubMed ID: 3282895
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus.
Coniff RF; Shapiro JA; Seaton TB
Arch Intern Med; 1994 Nov; 154(21):2442-8. PubMed ID: 7979840
[TBL] [Abstract][Full Text] [Related]
12. One-year acarbose treatment raises fasting serum acetate in diabetic patients.
Wolever TM; Radmard R; Chiasson JL; Hunt JA; Josse RG; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH
Diabet Med; 1995 Feb; 12(2):164-72. PubMed ID: 7743764
[TBL] [Abstract][Full Text] [Related]
13. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study.
Hotta N; Kakuta H; Sano T; Matsumae H; Yamada H; Kitazawa S; Sakamoto N
Diabet Med; 1993 Mar; 10(2):134-8. PubMed ID: 8458189
[TBL] [Abstract][Full Text] [Related]
14. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
[TBL] [Abstract][Full Text] [Related]
15. Treatment of poorly controlled non-insulin-dependent diabetic patients with Acarbose.
Scott RS; Knowles RL; Beaven DW
Aust N Z J Med; 1984 Oct; 14(5):649-54. PubMed ID: 6397178
[TBL] [Abstract][Full Text] [Related]
16. Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes.
Wolever TM; Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH
Int J Obes Relat Metab Disord; 1997 Sep; 21(9):756-63. PubMed ID: 9376887
[TBL] [Abstract][Full Text] [Related]
17. European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses.
Fischer S; Hanefeld M; Spengler M; Boehme K; Temelkova-Kurktschiev T
Acta Diabetol; 1998 Apr; 35(1):34-40. PubMed ID: 9625287
[TBL] [Abstract][Full Text] [Related]
18. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.
Coniff RF; Shapiro JA; Robbins D; Kleinfield R; Seaton TB; Beisswenger P; McGill JB
Diabetes Care; 1995 Jun; 18(6):817-24. PubMed ID: 7555508
[TBL] [Abstract][Full Text] [Related]
19. A risk-benefit appraisal of acarbose in the management of non-insulin-dependent diabetes mellitus.
Santeusanio F; Compagnucci P
Drug Saf; 1994 Dec; 11(6):432-44. PubMed ID: 7727053
[TBL] [Abstract][Full Text] [Related]
20. [Effect of acarbose on carbohydrate and lipid metabolism in type II diabetes with secondary failure].
Heuer LJ; Kaufmann HH
Dtsch Z Verdau Stoffwechselkr; 1985; 45(2):52-8. PubMed ID: 3924553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
